Pentoxifylline

己酮可可碱
  • 文章类型: Journal Article
    不孕症是指在一段合理的时间(12个月)后没有使用避孕药具或由于一个人丧失生育能力而无法怀孕,无论是独立还是与配偶。精子的产生和成熟问题是男性不育的最常见原因。运动性是决定精子受精能力的主要功能特征。因此,本研究的目的是获得弱精子症患者体外更好的某些精子功能参数。
    世界卫生组织(WHO)和许多研究认为不孕症是一种疾病,因此许多夫妇抱怨辅助生殖技术(ART)程序不成功,以克服他们的问题。本研究的目的是通过结合运动诱导来改善弱精子症精液患者的某些精子功能特征。L-肉碱和己酮可可碱可增强培养基以改善某些精子特征,可用于ART中心。
    从参与本研究的90名弱精子症患者中收集精液等分,射精正常的精液样本的体积在1.4-6ml之间,可以使用移液管或锥形刻度管进行测量;纳入标准是无精子症,少精子症和畸形精子症男性,不育的特发性男性也是,肥沃的正常精子症男性。虽然排除标准是无精子症男性,酒鬼,接受抗生素治疗的患者和精索静脉曲张的男性。样本随机分成两个相等的组。使用火腿的F12培养基,一部分作为对照组,另一个是治疗组,通过混合以下成分混合,玛卡粉提取物(Lepidiummeyenii)(M)1mg/ml,0.5mg/ml左旋肉碱(LC),和10mg/ml己酮可可碱(PTX)。使用社会科学统计软件包(SPSS)23.0版分析数据。描述性统计数据包括频率,范围,平均值和标准误差,来自处理组和对照组的数据表示为平均值±SEM,并使用Studentt检验比较实验组和对照组之间的值。分层方法用于研究体外激活前后的精子参数。
    信息显示,活跃的精子运动性A级有非常大的(p<0.001)增加,与HamsF12培养基和激活前相比,通过新型组合培养基分层技术激活后,形态学正常精子(MNS)显着增加,DNA片段化指数降低的进行性运动百分比。
    本工作指出,新型组合介质(LC,maca和PXT)具有改善男性不育因素中精子特征的潜在作用,建议在ART计划中用于精子制备和激活。
    UNASSIGNED: Infertility is an inability to conceive after a reasonable period of time (12 months) without the use of contraception or due to a person\'s incapacity to procreate, whether independently or with a spouse. Problems with the production and maturation of sperm are the most common causes of male infertility additionally; the motility is the major functional character that determines the fertilizing ability of spermatozoa. Therefore the goal of this study is to get better certain sperm function parameters in vitro of asthenozoospermic patient.
    UNASSIGNED: The World Health Organization (WHO) and many studies considered the infertility as a disease and so many couples complaining from unsuccessful assisted reproductive technologies (ART) procedures to overcome their problem. The goal of this study is to improve certain sperm function feature in vitro of asthenozoospermic semen patients by using combination of motility inducing namely; Maca, L-carnitine and Pentoxifylline that enhance the medium to improve certain sperm characters that might be utilized for ART centers.
    UNASSIGNED: Semen aliquots were collected from ninety patients with asthenozoospermia who participated in present study, the volume of semen samples with normal ejaculate when was ranged between 1.4-6ml and can be measured by using a measure pipette or conical graduated tube; Inclusion criteria was Asthenozoospermia, oligozoospermia and teratozoospermia men, Infertile idiopathic men also, fertile normozoospermic men. While Exclusion criteria was Azoospermic men, Alcoholic, Patients under treatment with antibiotics and men with Varicocele. The samples split into two equal groups at random. Using Ham\'s F12 medium, one portion served as the control group, and the other was the treatment group, which was mixing by combining the following ingredients, Maca powder extracts (Lepidium meyenii) (M) 1 mg/ml, 0.5 mg/ml of L-Carnitine (LC), and 10 mg/ml of Pentoxifylline (PTX). The data were analyzed using Statistical Package for Social Sciences (SPSS) version 23.0. The descriptive statistics including frequency, range, mean and standard error, Data from treated and control groups were expressed as mean ± SEM and to compare value between experimental and control groups using Students t-test. Layering approach is used to investigate sperm parameters before and after in vitro activation.
    UNASSIGNED: The information showed a very large (p< 0.001) increase in active sperm motility grade A, percentage of progressive motility with significant increase in morphologically normal sperm (MNS) with decreased in DNA fragmentation index after activation by layering technique with novel combination medium compared to Hams F12 medium and before activation.
    UNASSIGNED: The present work stated that novel combination medium (LC, maca and PXT) have potential effects to improve sperm characters in male infertility factors and suggested to be used for sperm preparation and activation in ART programs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:糖尿病肾病(DKD)与心血管疾病(CVD)的高风险相关。己酮可可碱(PTF),一种具有抗炎作用的非选择性磷酸二酯酶抑制剂,抗增殖,和抗纤维化作用,在临床试验和荟萃分析中都证明了肾脏的益处。本工作旨在研究PTF对糖尿病和中度至重度慢性肾脏疾病(CKD)患者亚临床动脉粥样硬化(SA)进展的影响。
    方法:在此开放标签中,随机对照,前瞻性单中心试点研究确定了102例2型糖尿病和CKD患者的颈动脉内中膜厚度(CIMT)和踝肱指数(ABI)的演变,18个月内服用阿司匹林或对照组。我们还确定了炎症标志物和Klotho(KL)水平的变化,一种维持心血管健康的蛋白质,以及它们与SA进展的关系。
    结果:接受PTF治疗的患者表现出更好的CIMT演变,外周血细胞(PBC)中KLmRNA水平升高,炎症状态降低。CIMT值的进展与血清中KL和PBC中mRNA表达水平的变化成反比。多元回归分析表明,PTF处理和PBCs中KLmRNA表达的变化,连同HDL的变化,是CIMT进展的显著决定因素(校正后R2=0.24,P<0.001),与传统危险因素无关。此外,这两个变量构成了对CIMT最差进展的保护因素[OR:0.103(P=0.001)和0.001(P=0.005),分别]。
    结论:PTF降低了CIMT变异评估的SA进展,与PBC中KL基因表达相关的有益作用。
    背景:研究方案代码为PTF-AA-TR-2009,该试验已在欧盟药物监管机构临床试验(EudraCT#2009-016595-77)上注册。验证日期为2010-03-09。
    BACKGROUND: Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and antifibrotic actions, has demonstrated renal benefits in both clinical trials and meta-analyses. The present work aimed to study the effects of PTF on the progression of subclinical atherosclerosis (SA) in a population of patients with diabetes and moderate to severe chronic kidney disease (CKD).
    METHODS: In this open-label, randomized controlled, prospective single-center pilot study the evolution of carotid intima-media thickness (CIMT) and ankle-brachial index (ABI) were determined in 102 patients with type 2 diabetes mellitus and CKD assigned to PTF, aspirin or control groups during 18 months. We also determined the variations in the levels of inflammatory markers and Klotho (KL), a protein involved in maintaining cardiovascular health, and their relationship with the progression of SA.
    RESULTS: Patients treated with PTF presented a better evolution of CIMT, increased KL mRNA levels in peripheral blood cells (PBCs) and reduced the inflammatory state. The progression of CIMT values was inversely related to variations in KL both in serum and mRNA expression levels in PBCs. Multiple regression analysis demonstrated that PTF treatment and variations in mRNA KL expression in PBCs, together with changes in HDL, were significant determinants for the progression of CIMT (adjusted R2 = 0.24, P < 0.001) independently of traditional risk factors. Moreover, both variables constituted protective factors against a worst progression of CIMT [OR: 0.103 (P = 0.001) and 0.001 (P = 0.005), respectively].
    CONCLUSIONS: PTF reduced SA progression assessed by CIMT variation, a beneficial effect related to KL gene expression in PBCs.
    BACKGROUND: The study protocol code is PTF-AA-TR-2009 and the trial was registered on the European Union Drug Regulating Authorities Clinical Trials (EudraCT #2009-016595-77). The validation date was 2010-03-09.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本研究旨在评估巴西粘膜利什曼病的四种治疗方法的成本效益:米尔特福辛,锑酸葡甲胺,结合和不结合己酮可可碱,和脂质体两性霉素B。采用的观点是巴西统一国家卫生系统(SUS)。感兴趣的结果是“治愈的患者”,这是使用决策树模型进行分析的。从科学文献中获得了直接成本和有效性的估计。单用抗蒙酸葡甲胺是基础比较策略;两性霉素B脂质体显示每个治愈患者的增量成本-效果比(ICER)为7,409.13美元,锑酸葡甲胺与己酮可可碱的组合显示的ICER为85.13美元。米替福辛绝对占主导地位,与锑酸葡甲胺相比,成本更高,效果相似。敏感性分析,将成本变化±25%,没有改变结果。然而,当米替福辛的成本估计低于171.23美元时,该策略比单独的锑酸葡甲胺占优势。结果证实,在所分析的方法中,用脂质体两性霉素B治疗仍然是具有最高ICER的选择。根据收购价格的变化,米替福辛可能具有成本效益,这值得关注,因为它是唯一可用的口头选择。其他方面的不核算阻止了立即使用这些结果来支持决策,但他们指出需要就粘膜利什曼病可用药物的价格进行谈判,并指出需要鼓励技术转让或其他旨在扩大巴西国家工业综合体表现的行动。
    This study aimed to estimate the cost-effectiveness of four therapeutic approaches available for mucosal leishmaniasis in Brazil: miltefosine, meglumine antimoniate, combined with and without pentoxifylline, and liposomal amphotericin B. The perspective adopted was that of the Brazilian Unified National Health System (SUS). The outcome of interest was \"cured patient\", which was analyzed using a decision tree model. Estimates of direct costs and effectiveness were obtained from the scientific literature. Meglumine antimoniate alone was the base comparator strategy; liposomal amphotericin B showed an incremental cost-effectiveness ratio (ICER) of USD 7,409.13 per cured patient, and the combination of meglumine antimoniate with pentoxifylline presented an ICER of USD 85.13. Miltefosine was absolutely dominated, with higher cost and similar effectiveness when compared to meglumine antimoniate. Sensitivity analyses, varying the cost by ±25%, did not change the results. However, when the cost of miltefosine was estimated at less than USD 171.23, this strategy was dominant over meglumine antimoniate alone. The results confirm that treatment with liposomal amphotericin B remains the option with the highest ICER among the approaches analyzed. Miltefosine may be cost-effective based on the variation in the acquisition price, which deserves attention because it is the only available oral option. The non-accounting of other aspects prevent the use of these results immediately to support decision-making, but they point out the need to negotiate the prices of drugs available for mucosal leishmaniasis and indicates the need of encouraging technology transfer or other actions aimed at expanding the performance of the Brazilian national industrial complex.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    严重的酒精性肝炎(SAH)是一种严重的疾病,治疗很少。通过改变肠-肝轴,建议将粪便微生物群移植(FMT)作为SAH的治疗方法。这项荟萃分析的目的是评估FMT与标准护理(SOC)在改善SAH患者生存率方面的功效。
    对电子数据库进行了彻底的搜索,直到2023年9月。比较接受FMT和SOC的SAH患者的生存率。使用ReviewManager5.4,计算具有95%置信区间(CI)的比值比(OR)。
    荟萃分析包括6项研究,共371例SAH患者。接受FMT的患者在1个月和3个月时的生存率明显高于接受SOC的患者,合并OR为2.91(95%CI:1.56-5.42,P=0.0008)和3.07(95%CI:1.81-5.20,P<0.0001),分别。然而,随访6个月(OR:2.96,95%CI:0.99~8.85,P=0.05)和1年(OR:1.81,95%CI:0.44~7.46,P=0.41)后生存优势消失。
    这项荟萃分析强调了FMT显著提高SAH患者短期生存率的潜力。然而,生存获益未持续6~12个月.这些发现要求对FMT的长期有效性进行更多研究,以及延长生存福利的策略。
    UNASSIGNED: Severe alcoholic hepatitis (SAH) is a serious condition with few treatments. By modifying the gut-liver axis, fecal microbiota transplantation (FMT) was proposed as a treatment for SAH. The purpose of this meta-analysis was to evaluate the efficacy of FMT versus the standard of care (SOC) in improving SAH patient survival rates.
    UNASSIGNED: A thorough search of electronic databases was conducted till September 2023. The survival rates of SAH patients undergoing FMT versus SOC were compared. Using Review Manager 5.4, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
    UNASSIGNED: The meta-analysis consisted of six studies with a total of 371 patients with SAH. Patients who received FMT had significantly higher survival rates at 1 and 3 months compared to those who received SOC, with pooled OR of 2.91 (95% CI: 1.56-5.42, P = 0.0008) and 3.07 (95% CI: 1.81-5.20, P < 0.0001), respectively. However, the survival advantage disappeared after 6 months (OR: 2.96, 95% CI: 0.99-8.85, P = 0.05) and 1 year of follow-up (OR: 1.81, 95% CI: 0.44-7.46, P = 0.41).
    UNASSIGNED: This meta-analysis highlights the potential of FMT to significantly improve short-term survival rates in SAH patients. However, the survival benefit did not last 6-12 months. These findings call for additional research into the effectiveness of FMT over the long term, along with strategies for extending the survival benefit.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    我们旨在评估银杏叶提取物(Gbe)的药物利用率,全身性皮质类固醇(CSs),和己酮可可碱(PTXF)通过分析电子患者健康记录数据来治疗急性耳鸣。此外,我们评估了不同的药物治疗是否与重复访问耳朵的不同频率相关,鼻子,喉咙(耳鼻喉科)医生。
    这项回顾性队列研究使用了来自IQVIA疾病分析仪(DA)数据库的数据。它包括在2005年1月至2021年12月之间由德国耳鼻喉科专家治疗的初始诊断耳鸣的患者。
    在满足所有选择标准的111,629名患者中,51,205收到了Gbe的处方,34,817个系统性CSs,和25,607的PTXF。与全身性CSs[比值比(OR)0.91;95%置信区间(CI):0.88-0.95]以及PTXF(OR0.74;95%CI:0.72-0.77)相比,Gbe处方因耳鸣而重复咨询的几率显着降低。这种关联在男性和女性以及某些年龄组中都很重要。
    Gbe是治疗急性耳鸣最常见的耳鼻喉科专科处方药。与全身性CSs和PTXF相比,患者再次咨询耳鸣专家的可能性降低。
    UNASSIGNED: We aimed to evaluate the drug utilization of Ginkgo biloba extract (Gbe), systemic corticosteroids (CSs), and pentoxifylline (PTXF) for the treatment of acute tinnitus by analyzing electronic patient health record data. In addition, we assessed whether the different drug treatments were associated with different frequencies of repeat visits to ear, nose, and throat (ENT) doctors.
    UNASSIGNED: This retrospective cohort study used data from the IQVIA Disease Analyzer (DA) database. It included patients with an initial diagnosis of tinnitus between January 2005 and December 2021, treated by ENT specialists in Germany.
    UNASSIGNED: Of 111,629 patients meeting all selection criteria, 51,205 received prescriptions of Gbe, 34,817 of systemic CSs, and 25,607 of PTXF. Gbe prescription was associated with significantly lower odds of a repeat consultation due to tinnitus compared to systemic CSs [odds ratio (OR) 0.91; 95% confidence interval (CI): 0.88-0.95] as well as PTXF (OR 0.74; 95% CI: 0.72-0.77). This association was significant in both men and women and in some age groups.
    UNASSIGNED: Gbe is the most frequently ENT specialist-prescribed drug for the treatment of acute tinnitus. It is associated with a reduced likelihood of patients consulting their ENT specialist for tinnitus again compared to systemic CSs and PTXF.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:免疫失调可以在抑郁症的病理生理学中发挥作用,研究表明,免疫拮抗剂可以改善难治性双相抑郁(TRD)患者的抑郁症状。
    目的:评价抗炎药的抗抑郁作用,己酮可可碱(PTX)在TRD双相I/II成人受试者中的应用。
    方法:这12周,随机化,双盲,安慰剂对照,在埃尔比勒的霍勒精神病医院和私人诊所进行了60名参与者的平行组试验,伊拉克。根据DSM-5标准,参与者被确认为符合双相I/II抑郁的资格。使用改良的意向治疗分析对数据进行分析。
    结果:两组在汉密尔顿抑郁量表(HAM-D-17)评分(χ2=1.9,P=0.48)或显著时间×治疗交互作用(χ2=7.1,P=0.54)方面无显著差异。然而,两组HAM-D-17评分从开始到终点均有显著的时间效应(χ2=2.11,P=0.002).此外,发现显著的时间×治疗×CRP交互作用(χ2=3.1,P=0.016),在CRP>7.1mg/L的PTX治疗的受试者中,HAM-D-17评分降低更多。PTX和安慰剂组之间的反应率差异未达到显着水平(χ2=0.84,p=0.43)。此外,血清TNF-α浓度,CRP,在PTX组中,IL-6和IL-6在第12周显著降低(分别为P=.007、.04和<.001)。
    结论:目前的概念验证研究发现,就双相情感障碍患者的整体抗抑郁效果而言,PTX并不优于安慰剂。然而,它可以改善治疗前炎症水平较高的受试者亚群的抑郁情绪.
    背景:NCT05324735。
    BACKGROUND: Immune dysregulation can play a role in depression pathophysiology, and immunological antagonists can improve depressive symptoms in treatment-resistant bipolar depression (TRD) patients according to studies.
    OBJECTIVE: To evaluate the anti-depressant effects of the anti-inflammatory drug, pentoxifylline (PTX) in TRD bipolar I/II adult subjects.
    METHODS: This 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of 60 participants was conducted at Hawler Psychiatric Hospital and Private Clinic in Erbil, Iraq. Participants were confirmed as being qualified for bipolar I/II depression based on DSM-5 criteria. Data were analyzed using modified intent-to-treat analysis.
    RESULTS: There were no significant differences between the two groups in Hamilton Rating Scale for Depression-17 (HAM-D-17) scores (χ2=1.9, P =.48) or a significant time × treatment interaction (χ2=7.1, P=.54). Nevertheless, a significant effect of time was observed with both groups\' reduction in HAM-D-17 scores from the start to the endpoint (χ2= 2.11, P=.002). Besides, a significant time × treatment × CRP interaction was found (χ2=3.1, P=0.016), where there was more reduction in HAM-D-17 score in PTX-treated subjects with CRP> 7.1 mg/L. The response rate difference between PTX and the placebo group did not reach a significance level (χ2=0.84, p=0.43). Furthermore, serum concentrations of TNF-α, CRP, and IL-6 significantly reduced at week 12 in the PTX group (P=.007,.04, and <.001, respectively).
    CONCLUSIONS: The current proof of concept study found that in terms of overall anti-depressant effectiveness in bipolar patients with TRD, PTX is not superior to placebo. However, it may improve depressive mood in a subpopulation of subjects with a higher pretreatment inflammatory profile.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • DOI:
    文章类型: Case Reports
    化脓性汗腺炎(HS)是一种慢性炎症性皮肤病,可能对患者的生活质量产生深远的影响。个性化的HS联合治疗是为患有多种疼痛疮的54岁女性开的处方,如下:纳曲酮胶囊从0.5mg滴定至4.5mg;己酮可可碱5%,利福平2%,克林霉素1%,和乙醇酸外用乳膏。使用两种疾病特异性结果测量观察到临床改善:Hurley分期系统和HS评分。患者的HS从II期(中度)改善至I期(轻度),HS评分从103分下降,报告了五个解剖区域,到19分,只有三个地区受到影响。此外,治疗前后的照片显示,沸腾/皮肤脓肿的数量明显减少,总体恢复。在患者自我报告的生活质量(化脓性汗腺炎生活质量评估)的所有领域也观察到改善。患者没有经历任何不良影响。可以定制复合药物以满足患者的特殊需要,并且可以在整个治疗过程中进行调整以匹配患者的个人进展。虽然需要进一步的研究,这种个性化,联合治疗可能是HS的关键治疗选择.
    Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease that may have profound effects on the patient\'s quality of life. A personalized HS combination therapy treatment was prescribed to a 54-year-old female suffering from multiple painful sores, as follows: naltrexone capsules titrated from 0.5 mg up to 4.5 mg; pentoxifylline 5%, rifampin 2%, clindamycin 1%, and glycolic acid topical cream. Clinical improvements were observed using two disease-specific outcome measures: Hurley Staging System and HS Score. The patient\'s HS improved from Stage II (moderate) to Stage I (mild), and the HS score decreased from 103 points with five anatomical regions reported, to 19 points with only three regions affected. Furthermore, the before and after treatment photographs showed a visible reduction in the number of boils/skin abscesses and an overall recovery. Improvements were also observed across all domains of the patient\'s self-reported quality of life (Hidradenitis Suppurativa Quality of Life Assessment). The patient did not experience any undesirable effects. Compounded medications may be customized to meet the patient\'s special needs and may be adjusted throughout the course of treatment to match the patient\'s individual progress. Although further studies are necessary, this personalized, combination therapy may be a key treatment option in HS.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    糖尿病肾病(DN)是一种进行性肾脏疾病,由于长期暴露于升高的血糖水平(BGL)而发展为糖尿病的并发症。在这种情况下,需要治疗部分的干预以靶向参与糖尿病的特定元素,以预防/延迟肾功能的恶化。因此,本研究的重点是设计和评估C肽(CPep)和抗糖尿病药物赖索碱(LSF)组合的有效纳米制剂,以预防链脲佐菌素(STZ)诱导的DN。作为战略干预,最初合成了LSF-油酸前药(LSF-OA),并进一步封装在内部合成的阳离子聚合物[(mPEG-b-P(CB-{g-DMDP}-co-LA);mPLM]中,以通过静电相互作用制备CPep的聚合物纳米复合物,具有218.6±14.4nm的尺寸和+5.2mV的zeta电位以及在25°C下30天的稳定性。mPLM-LSF-OA-CPep纳米颗粒显示与红细胞的血液相容性,并通过降低亚硝酸盐水平表现出有效的抗氧化活性,诱导抗氧化剂GSH的释放并保护代谢应激的大鼠肾脏和小鼠胰岛素瘤细胞免于凋亡。体内药代动力学描述了大鼠体内t½和平均停留时间的增加,与游离LSF和CPep相比,用mPLM-LSF-OA-CPep治疗时,进一步改善了STZ诱导的DN动物模型的BGL和肾脏状况,并降低了血浆IL-6和TNF-α水平。此外,血浆胰岛素水平的升高和胰岛中增殖标记细胞的检测表明糖尿病动物中β细胞的再生。
    Diabetic nephropathy (DN) is a progressive kidney disorder that develops as a complication of diabetes due to long-term exposure to elevated blood glucose levels (BGLs). In this case, an intervention of therapeutic moieties is needed to target the specific elements involved in diabetes to prevent/delay the deterioration of kidney function. Therefore, the present study focused on designing and evaluating a potent nano-formulation of a combination of C-peptide (CPep) and the anti-diabetic drug lisofylline (LSF) to prevent streptozotocin (STZ)-induced DN. As a strategic intervention, an LSF-oleic acid prodrug (LSF-OA) was initially synthesized and further encapsulated in an in-house-synthesized cationic polymer [(mPEG-b-P(CB-{g-DMDP}-co-LA)); mPLM] to prepare polymeric nano-complexes of CPep via electrostatic interaction, possessing a size of 218.6 ± 14.4 nm and zeta potential of +5.2 mV together with stability for 30 days at 25 °C. mPLM-LSF-OA-CPep nanoparticles demonstrated hemocompatibility with RBCs and exhibited potent anti-oxidant activity by reducing nitrite levels, inducing the release of anti-oxidant GSH and protecting metabolically stressed rat kidneys and murine insulinoma cells from apoptosis. In vivo pharmacokinetics depicted an increase in t½ and mean residence time in rats, which further improved the BGL and renal conditions and reduced plasma IL-6 and TNF-α levels in the STZ-induced DN animal model when treated with mPLM-LSF-OA-CPep compared to free LSF and CPep. Moreover, an increase in the plasma insulin level and detection of proliferative marker cells in pancreatic islets suggested the regeneration of β-cells in diabetic animals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    Livedoid血管病变(LV)是一种慢性,以下肢疼痛性溃疡为特征的复发性血栓性血管病变,慢慢愈合,留下萎缩性白色伤疤,被称为“萎缩性白斑”。“本报告介绍了一名31岁女性的病例,她的腿和脚有4年的复发性疼痛性溃疡史。皮肤活检显示与LV一致,详尽的实验室检查排除了次要原因,例如血栓形成,恶性肿瘤,自身免疫性疾病,和外周动脉疾病。患者在己酮可可碱的治疗方案下表现出明显的改善,硝苯地平,还有华法林,导致溃疡完全消退和持续缓解超过5个月。我们的案例强调了综合诊断方法和多学科治疗策略在管理原发性LV以实现缓解和预防皮肤溃疡复发方面的重要性。
    Livedoid vasculopathy (LV) is a chronic, recurrent thrombotic vasculopathy characterized by painful ulcerations on the lower extremities, which heal slowly and leave atrophic white scars known as \"atrophie blanche.\" This report presents the case of a 31-year-old woman with a 4-year history of recurrent painful ulcerations on her legs and feet. A skin biopsy revealed findings consistent with LV, and an exhaustive laboratory workup ruled out secondary causes such as thrombophilia, malignancies, autoimmune diseases, and peripheral arterial disease. The patient showed remarkable improvement with a treatment regimen of pentoxifylline, nifedipine, and warfarin, resulting in complete ulcer resolution and sustained remission over 5 months. Our case highlights the importance of a comprehensive diagnostic approach and a multidisciplinary treatment strategy in managing primary LV to achieve remission and prevent recurrence of skin ulcerations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号